Liver fibrosis progression in chronic hepatitis B patients positive for hepatitis B e antigen: A prospective cohort study with paired transient elastography examination

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 11, 2013, Pages 1762-1769

  Wong, Grace Lai Hung ^a   Chan, Henry Lik Yuen ^a   Yu, Zhuo ^a   Chan, Hoi Yun ^a   Tse, Chi Hang ^a   Wong, Vincent Wai Sun ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Alanine aminotransferase; Antiviral therapy; HBeAg; HBsAg; HBV DNA; Liver stiffness measurement

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL EVALUATION; COHORT ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; ELASTOGRAPHY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HETEROZYGOTE; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOREACTIVITY; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEROCONVERSION; THROMBOCYTE;

ALANINE AMINOTRANSFERASE; ANTIVIRAL THERAPY; HBEAG; HBSAG; HBV DNA; LIVER STIFFNESS MEASUREMENT;

ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; DISEASE PROGRESSION; ELASTICITY IMAGING TECHNIQUES; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INCIDENCE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84897583638     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12312     Document Type: Article

References (26)

1. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 373: 582-592.
2. Yang HI, Lu SN, Liaw YF etal. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N. Engl. J. Med. 2002; 347: 168-174.
3. Lok AS, Lai CL. A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children. Hepatology 1988; 8: 1130-1133.
4. Feld JJ, Heathcote EJ. Hepatitis B e antigen-positive chronic hepatitis B: natural history and treatment. Semin. Liver Dis. 2006; 26: 116-129.
5. Chan HL, Jia J. Chronic hepatitis B in Asia-new insights from the past decade. J. Gastroenterol. Hepatol. 2011; 26 (Suppl. 1): 131-137.
6. Wong GL, Wong VW, Choi PC etal. Clinical factors associated with liver stiffness in hepatitis B e antigen-positive chronic hepatitis B patients. Clin. Gastroenterol. Hepatol. 2009; 7: 227-233.
7. European Association for the Study of the L. EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J. Hepatol. 2012; 57: 167-185.
8. Liaw YF, Sung JJ, Chow WC etal. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 2004; 351: 1521-1531.
9. Hui CK, Leung N, Yuen ST etal. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology 2007; 46: 395-401.
10. Fujiwara A, Sakaguchi K, Fujioka S etal. Fibrosis progression rates between chronic hepatitis B and C patients with elevated alanine aminotransferase levels. J. Gastroenterol. 2008; 43: 484-491.
11. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N. Engl. J. Med. 2001; 344: 495-500.
12. Wong VW, Chan HL. Transient elastography. J. Gastroenterol. Hepatol. 2010; 25: 1726-1731.
13. Chan HL, Wong GL, Choi PC etal. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J. Viral Hepat. 2009; 16: 36-44.
14. Wong GL, Wong VW, Choi PC etal. Evaluation of alanine transaminase and hepatitis B virus DNA to predict liver cirrhosis in hepatitis B e antigen-negative chronic hepatitis B using transient elastography. Am. J. Gastroenterol. 2008; 103: 3071-3081.
15. Wong GL, Wong VW, Choi PC etal. On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients. Antivir. Ther. 2011; 16: 165-172.
16. Wong GL, Wong VW, Choi PC etal. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut 2009; 58: 111-117.
17. Chan HL, Chui AK, Lau WY etal. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation. J. Med. Virol. 2002; 68: 182-187.
18. Chan HL, Thompson A, Martinot-Peignoux M etal. Hepatitis B surface antigen quantification: why and how to use it in 2011-a core group report. J. Hepatol. 2011; 55: 1121-1131.
19. Wong GL, Wong VW, Choi PC etal. Assessment of fibrosis by transient elastography compared with liver biopsy and morphometry in chronic liver diseases. Clin. Gastroenterol. Hepatol. 2008; 6: 1027-1035.
20. Liaw YF, Kao JH, Piratvisuth T etal. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol. Int. 2012; 6: 531-561.
21. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
22. Lai M, Hyatt BJ, Nasser I, Curry M, Afdhal NH. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J. Hepatol. 2007; 47: 760-767.
23. Chang TT, Liaw YF, Wu SS etal. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886-893.
24. Marcellin P, Gane E, Buti M etal. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381: 468-475.
25. Hsu YS, Chien RN, Yeh CT etal. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35: 1522-1527.
26. Prati D, Taioli E, Zanella A etal. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann. Intern. Med. 2002; 137: 1-10.